Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution’s Three Decade Experience

(2014) Florent Malard et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT

(2014) S Dirou et al.   BONE MARROW TRANSPLANTATION

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome

(2014) A Nagler et al.   BONE MARROW TRANSPLANTATION

How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation

(2014) Enric Carreras   BRITISH JOURNAL OF HAEMATOLOGY

Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

(2014) Mohamad Mohty et al.   CANCER

Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus–Sirolimus on Endothelial Cells: Protective Effect of Defibrotide

(2013) Alba Carmona et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content

(2013) B. J. Trottier et al.   BLOOD

BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation

(2013) Fiona L. Dignan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2013) Arnon Nagler et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Novel Insights to Pathogenesis, Current Status of Treatment, and Future Directions

(2012) P.G. Richardson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Drug safety evaluation of defibrotide

(2012) Paul G Richardson et al.   Expert Opinion On Drug Safety

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

(2012) Selim Corbacioglu et al.   LANCET

The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade

(2011) Enric Carreras et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The role of the endothelium in the short-term complications of hematopoietic SCT

(2011) E Carreras et al.   BONE MARROW TRANSPLANTATION

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation

(2010) Marta Palomo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial

(2010) Paul G. Richardson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination

(2010) Shlomo Almog et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT

(2010) N Cantoni et al.   BONE MARROW TRANSPLANTATION

Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation

(2010) L. Marsa-Vila et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

(2010) Ted A. Gooley et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Release of Soluble Factors Contributing to Endothelial Activation and Damage after Hematopoietic Stem Cell Transplantation Is Not Limited to the Allogeneic Setting and Involves Several Pathogenic Mechanisms

(2009) Marta Palomo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

(2009) Jason A. Coppell et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Vascular endothelium and graft-versus-host disease

(2008) Barbara C. Biedermann   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation

(2008) C. Cutler et al.   BLOOD

Iron overload in hematopoietic cell transplantation

(2008) N S Majhail et al.   BONE MARROW TRANSPLANTATION

The Contribution of Endothelial Activation and Injury to End-Organ Toxicity following Allogeneic Hematopoietic Stem Cell Transplantation

(2007) Kenneth R. Cooke et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION